RNS Number : 2528K
RUA Life Sciences PLC
23 August 2023
 

23 August 2023

 

 

RUA Life Sciences plc

 

("RUA" the "Company" or the "Group")

 

Result of AGM

 

RUA Life Sciences plc (AIM:RUA.L), the holding company of a group of medical device businesses focussed on the exploitation of the world's leading long-term implantable biostable polymer (Elast-Eon ™), announces that all resolutions put forward to its Annual General Meeting held earlier today were duly passed and the votes cast were as follows:

 

Res No.

Votes For

%

Votes Against

%

Votes Total

% I.S.C.

Votes Withheld

1

3,120,357

100.00%

0

0.00%

3,120,357

14.07

0

2

2,229,757

71.48%

889,792

28.52%

3,119,549

14.06

808

3

2,955,917

95.24%

147,790

4.76%

3,103,707

13.99

16,650

4

2,951,476

95.23%

147,790

4.77%

3,099,266

13.97

21,091

5

3,093,484

99.67%

10,223

0.33%

3,103,707

13.99

16,650

6

2,980,778

95.53%

139,356

4.47%

3,120,134

14.06

223

7

2,980,448

95.53%

139,569

4.47%

3,120,017

14.06

340

8

2,951,597

95.48%

139,569

4.52%

3,091,166

13.93

29,191

 

The full text of each of the resolutions is set out in the notice of Annual General Meeting, copies of which are available on the Company's website (www.rualifesciences.com).

QCA Code - statement regarding voting result

The board notes that although Resolution 2 (remuneration committee report) passed with the requisite majority, it received more than 20% of votes against the board's recommendation. We thank shareholders for their support and the Board will look to continue engagement throughout the year. The board encourages an open and constructive dialogue directly with shareholders and continue to be willing to engage with any shareholder on any relevant topics should they so wish.

For further information contact:

RUA Life Sciences

Bill Brown, Chairman                                                                Tel: +44 (0)1294 317073  

Dr Caroline Stretton, Group MD                                             Tel: +44 (0)1294 317073

 

Cenkos Securities plc (Nominated Adviser and Broker)   Tel: +44 (0)20 7397 8900

Giles Balleny / Max Gould (Corporate Finance)

Michael Johnson (Sales)

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
RAGPJMATMTBTBAJ